PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107

被引：0
|
作者：
Freeman, Mason W. [1 ]
Bond, Mary [2 ]
Murphy, Brian [2 ]
Hui, James [1 ]
Isaacson, Jonathan [2 ]
机构：
[1] CinCor Pharma Inc, Boston, MA USA
[2] CinRx Pharma LLC, Cincinnati, OH USA
来源：
JOURNAL OF HYPERTENSION | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
S-16-4
引用
收藏
页码：E42 / E43
页数：2
相关论文
共 50 条
  • [1] Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
    Freeman, M.
    Bond, M.
    Murphy, B.
    Isaacsohn, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2200 - 2200
  • [2] Results From a Phase 1 Study Demonstrating the Safety and Pharmacokinetics of the Aldosterone Synthase Inhibitor CIN-107 in Subjects With Varying Degrees of Renal Function
    Freeman, Mason W.
    Halvorsen, Yuan-Di
    Bond, Mary
    Murphy, Brian
    Isaacsohn, Jonathan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 527 - 528
  • [3] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
    Freeman, Mason W.
    Bond, Mary
    Murphy, Brian
    Hui, James
    Isaacsohn, Jonathan
    HYPERTENSION RESEARCH, 2023, 46 (01) : 108 - 118
  • [4] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
    Mason W. Freeman
    Mary Bond
    Brian Murphy
    James Hui
    Jonathan Isaacsohn
    Hypertension Research, 2023, 46 : 108 - 118
  • [5] First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
    Shimizu, Hidetoshi
    Tortorici, Michael A.
    Ohta, Yoshiyasu
    Ogawa, Kei
    Rahman, Sheikh Mohammed Ashfaq
    Fujii, Aya
    Hiraga, Yuki
    Kawai, Mizue
    Sugimoto-Kawabata, Kanami
    van Iersel, Mattheus
    van Lier, Jan Jaap
    Djedjos, Stephen
    Slingsby, B. T.
    Rodman, David M.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (08):
  • [6] ASCENDING MULTIPLE-DOSE STUDY WITH PONESIMOD, A SELECTIVE SIP1 RECEPTOR AGONIST: TOLERABILITY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS
    Brossard, P.
    Maatouk, H.
    Halabi, A.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S93 - S93
  • [7] A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects
    Yue, Patrick
    Qu, Emma
    Pan, Jie
    Weitz, Jeffrey
    Ji, Qunsheng
    BLOOD, 2024, 144 : 4009 - 4010
  • [8] Results from a phase 1 study investigating the safety and pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in subjects with varying degrees of hepatic function
    Hui, James
    Halvorsen, Yuan-Di
    Bond, Mary
    Murphy, Brian
    Isaacsohn, Jonathan
    Freeman, Mason W.
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 246 - 247
  • [9] Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
    Jin, Byung Hak
    Hong, Taegon
    Yoo, Byung Won
    Kim, Choon Ok
    Kim, Dasohm
    Kim, Youn Nam
    Park, Min Soo
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (10):
  • [10] Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers
    Gurov, Xiaoshu Dai
    Merica, Elizabeth
    Iyer, Varsha
    Claeys, Annie
    Patil, Spurthi
    Urbstonaitis, Rolandas
    Xiao, James
    Callaghan, Michael U.
    BLOOD, 2022, 140 : 5426 - 5427
12345